1
|
Venturini N, Cerpa L, Kandratavicius N, Manta G, Cóndor-Luján B, Pereira J, Figueira RCL, Muniz P. Biogeochemical and oceanographic conditions provide insights about current status of an Antarctic fjord affected by relatively slow glacial retreat. AN ACAD BRAS CIENC 2023; 95:e20230451. [PMID: 38055512 DOI: 10.1590/0001-3765202320230451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 06/06/2023] [Indexed: 12/08/2023] Open
Abstract
Understand the origin, transport, and character of organic matter entering Antarctic fjords is essential as they are major components of the global carbon cycle and budget. Macromolecular pools of particulate organic matter, bulk organic geochemistry, major and trace elements in surface sediments from Collins Bay were analysed as source indicators. Oceanographic conditions, bathymetry (multibeam) and grain size were considered as environmental controlling factors. Sediment samples were taken with a van Veen grab, during the ANTAR XXV Peruvian expedition (February 2018), onboard the R/V "BAP Carrasco" from the Peruvian Navy. Biopolymeric composition revealed the predominance of fresh marine protein-rich organic matter in the seafloor of Collins Bay, denoting high quality food resource for marine benthic heterotrophs. Based on Igeo values (between 0 and 1) Collins Bay can be considered unpolluted with natural levels of As, Cd, Cr, Cu, Fe, Mn, Ni, Pb and Zn. Distribution of most of these elements with a gradient of decrease from the shallow inner fjord towards the outer deepest fjord, suggest their association with the deposition of detrital material and lithogenic particles supplied by Collins Glacier frontal ablation and runoff. This first comprehensive baseline information would assist in interpreting downcore sedimentary reconstructions and future climate-induce changes.
Collapse
Affiliation(s)
- Natalia Venturini
- Universidad de la República, Oceanografía y Ecología Marina (OEM), Instituto de Ecología y Ciencias Ambientales (IECA), Facultad de Ciencias, Iguá 4225, 11400, Montevideo, Uruguay
| | - Luis Cerpa
- Instituto Geológico, Minero y Metalúrgico (INGEMMET), Av. Canadá 1470, San Borja, 15034, Lima, Perú
| | - Noelia Kandratavicius
- Universidad de la República, Oceanografía y Ecología Marina (OEM), Instituto de Ecología y Ciencias Ambientales (IECA), Facultad de Ciencias, Iguá 4225, 11400, Montevideo, Uruguay
| | - Gastón Manta
- Universidad de la República, Departamento de Ciencias de la Atmósfera y Física de los Océanos (DCAFO), Facultad de Ciencias, Iguá 4225, 11400, Montevideo, Uruguay
| | - Báslavi Cóndor-Luján
- Universidad Científica del Sur, Facultad de Ciencias Veterinarias y Biológicas, Carrera de Biología Marina, Antigua Panamericana Sur km 19, Villa El Salvador, 15067, Lima, Perú
| | - Jennifer Pereira
- Universidad de la República, Oceanografía y Ecología Marina (OEM), Instituto de Ecología y Ciencias Ambientales (IECA), Facultad de Ciencias, Iguá 4225, 11400, Montevideo, Uruguay
| | - Rubens C L Figueira
- Universidade de São Paulo, Instituto Oceanográfico, Laboratorio de Química Inorgânica Marinha, Praça do Oceanográfico, 191, 05508-120 São Paulo, SP, Brazil
| | - Pablo Muniz
- Universidad de la República, Oceanografía y Ecología Marina (OEM), Instituto de Ecología y Ciencias Ambientales (IECA), Facultad de Ciencias, Iguá 4225, 11400, Montevideo, Uruguay
| |
Collapse
|
2
|
Tomé I, Alves-Pimenta S, Sargo R, Pereira J, Colaço B, Brancal H, Costa L, Ginja M. Mechanical osteoarthritis of the hip in a one medicine concept: a narrative review. BMC Vet Res 2023; 19:222. [PMID: 37875898 PMCID: PMC10599070 DOI: 10.1186/s12917-023-03777-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 10/06/2023] [Indexed: 10/26/2023] Open
Abstract
Human and veterinary medicine have historically presented many medical areas of potential synergy and convergence. Mechanical osteoarthritis (MOA) is characterized by a gradual complex imbalance between cartilage production, loss, and derangement. Any joint instability that results in an abnormal overload of the joint surface can trigger MOA. As MOA has a prevailing mechanical aetiology, treatment effectiveness can only be accomplished if altered joint mechanics and mechanosensitive pathways are normalized and restored. Otherwise, the inflammatory cascade of osteoarthritis will be initiated, and the changes may become irreversible. The management of the disease using non-steroidal anti-inflammatory drugs, analgesics, physical therapy, diet changes, or nutraceuticals is conservative and less effective. MOA is a determinant factor for the development of hip dysplasia in both humans and dogs. Hip dysplasia is a hereditary disease with a high incidence and, therefore, of great clinical importance due to the associated discomfort and significant functional limitations. Furthermore, on account of analogous human and canine hip dysplasia disease and under the One Medicine concept, unifying veterinary and human research could improve the well-being and health of both species, increasing the acknowledgement of shared diseases. Great success has been accomplished in humans regarding preventive conservative management of hip dysplasia and following One Medicine concept, similar measures would benefit dogs. Moreover, animal models have long been used to better understand the different diseases' mechanisms. Current research in animal models was addressed and the role of rabbit models in pathophysiologic studies and of the dog as a spontaneous animal model were highlighted, denoting the inexistence of rabbit functional models to investigate therapeutic approaches in hip MOA.
Collapse
Affiliation(s)
- I Tomé
- Department of Veterinary Sciences, University of Trás-Os-Montes E Alto Douro, Vila Real, 5000-801, Portugal.
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal.
| | - S Alves-Pimenta
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
- Department of Animal Science, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
| | - R Sargo
- Department of Veterinary Sciences, University of Trás-Os-Montes E Alto Douro, Vila Real, 5000-801, Portugal
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
| | - J Pereira
- Department of Veterinary Sciences, University of Trás-Os-Montes E Alto Douro, Vila Real, 5000-801, Portugal
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
| | - B Colaço
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
- Department of Animal Science, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
| | - H Brancal
- Clínica Veterinária da Covilhã, Covilhã, 6200-289, Portugal
| | - L Costa
- Department of Veterinary Sciences, University of Trás-Os-Montes E Alto Douro, Vila Real, 5000-801, Portugal
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
| | - M Ginja
- Department of Veterinary Sciences, University of Trás-Os-Montes E Alto Douro, Vila Real, 5000-801, Portugal
- CECAV, Centre for Animal Sciences and Veterinary Studies, Associate Laboratory for Animal and Veterinary Science - AL4AnimalS, University of Trás-Os-Montes E Alto Douro, Vila Real, Portugal
| |
Collapse
|
3
|
Vieira E Brito D, Fereira A, Pereira J, Pereira-Lourenço M, Godinho R, Pereira B, Peralta P, Conceiçao P, Reis Mario A, Paula Rabaça C. Prior MRI-imaging impact of patients submitted to brachytherapy for prostate cancer. Actas Urol Esp 2023; 47:503-508. [PMID: 37086843 DOI: 10.1016/j.acuroe.2023.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 03/05/2023] [Accepted: 03/06/2023] [Indexed: 04/24/2023]
Abstract
INTRODUCTION Brachytherapy for the treatment of prostate cancer is a well-established option. Use of Multiparametric Magnetic Resonance Imaging (mpMRI) for staging and diagnosis of prostate cancer has come to change the current paradigm. In this study we aim to assess the impact of performing mpMRI to evaluate the presence of extracapsular lesions before brachytherapy in patients with prostate cancer concerning biochemical recurrence and time to nadir. METHODS Review data from 73 patients submitted to brachytherapy. The following factors were evaluated: age, initial PSA, MRI local staging results, ISUP, nadir, time to nadir, PSA at one-year, biochemical recurrence, and time to recurrence. RESULTS Median age was 68 years (51-72) and median follow-up 53 months (30-72). Concerning imaging modality 30,1% (n = 22) patients performed mpMRI. In the mpMRI group, 90.9% (n = 20) had at least one suspect lesion on mpMRI. Time to nadir was 27 months (3-64) in patients where mpMRI was not performed and 23.5 months (2-48) in patients submitted to mpMRI (P = .244). The median value of nadir was 0.42 ng/mL (<0.001-2) in patients submitted to mpMRI and vs 0.28 ng/mL (<0.001-4) in patients without MRI (P = .062) Recurrence utilizing Phoenix criteria was 9% (n = 2) in patients with MRI and 9.2% (n = 5) without mpMRI (P = .456), median follow-up of 43 months (12-72) for the MRI group with 58 months (30-78) for the non-mpMRI group. Both groups were statistically similar. CONCLUSION Our results allow us to conclude that in our series MRI did not influence biochemical recurrence, time to nadir, or nadir value.
Collapse
Affiliation(s)
- D Vieira E Brito
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal.
| | - A Fereira
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - J Pereira
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - M Pereira-Lourenço
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - R Godinho
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - B Pereira
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - P Peralta
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - P Conceiçao
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| | - A Reis Mario
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal; Servicio de Radioterapia, Instituto Portugués de Oncología, Coimbra, Portugal
| | - C Paula Rabaça
- Servicio de Urología, Instituto Portugués de Oncología, Coimbra, Portugal
| |
Collapse
|
4
|
Gouveia R, Madureira S, Elias C, Neves A, Soares PR, Soares-Carreira M, Pereira J, Ribeiro A, Amorim M, Almeida J, Araújo J, Lourenco P. Lower low density lipoprotein cholesterol associates to higher mortality in non-diabetic heart failure patients. Int J Cardiol Cardiovasc Risk Prev 2023; 18:200197. [PMID: 37521244 PMCID: PMC10374454 DOI: 10.1016/j.ijcrp.2023.200197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 06/17/2023] [Accepted: 07/13/2023] [Indexed: 08/01/2023]
Abstract
Background In patients with established heart failure (HF) low total cholesterol levels associate with worse prognosis. Evidence concerning the impact of Low-density lipoprotein cholesterol (LDL-c) in HF is scarce. We aimed to evaluate the prognostic impact of LDL-c in patients with HF, both with and without diabetes mellitus (DM). Methods We retrospectively analyzed outpatients with chronic HF with systolic dysfunction followed in our HF clinic from January/2012 to May/2018. LDL-c was calculated using the Friedewald's formula. Patients without a complete lipid profile were excluded. The endpoint under analysis was all-cause mortality. Patients were followed until January/2021. A Cox-regression analysis was used to study the prognostic impact of LDL-c. The LDL-c cut-off used was 100 mg/dL (mean value). Analysis was stratified according to the coexistence of DM. Multivariate models were built adjusting for age, sex, coronary artery disease, atherosclerotic non-coronary artery disease, arterial hypertension, smoking status, statin use, severity of systolic dysfunction, creatinine clearance and evidence-based therapy. Results We studied 522 chronic HF patients, mean age was 70 years, 66.5% males. Severe systolic dysfunction was present in 42.7%, 30.5% had coronary heart disease, 60.5% had arterial hypertension, 41.6% had DM. A total of 92.0% were treated with beta blocker, 87.5% with an ACEi/ARB and 29.1% with a MRA. During a median follow-up of 53 (interquartile range 33-73) months, 235 (45%) patients died. Patients with LDL-c ≤100 mg/dL presented increased multivariate-adjusted risk of all-cause mortality: HR = 1.58 (95% CI: 1.08-2.30), p = 0.02. When patients were stratified according to DM, LDL-c ≤100 mg/dL was independently associated with increased death risk - HR = 1.55 (95% CI:1.05-2.30), p = 0.03 in patients without DM; in patients with DM no association was detected - multivariate-adjusted HR = 1.18 (95% CI: 0.77-1.80), p = 0.44. Conclusion Non-DM HF patients with LDL-c>100 mg/dL have a 35% reduction in the mortality risk when compared with those with lower values. The "cholesterol paradox" in HF also applies to LDL-c in non-DM patients.
Collapse
Affiliation(s)
- R. Gouveia
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - S. Madureira
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - C. Elias
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - A. Neves
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - P. Ribeirinho Soares
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - M. Soares-Carreira
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - J. Pereira
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
- Faculty of Medicine, Porto University, Portugal
| | - A. Ribeiro
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - M. Amorim
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - J. Almeida
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Cardiovascular R&D Centre, Faculty of Medicine, Porto University, Portugal
| | - J.P. Araújo
- Faculty of Medicine, Porto University, Portugal
- Cardiovascular R&D Centre, Faculty of Medicine, Porto University, Portugal
| | - P. Lourenco
- Internal Medicine Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal
- Faculty of Medicine, Porto University, Portugal
- Cardiovascular R&D Centre, Faculty of Medicine, Porto University, Portugal
| |
Collapse
|
5
|
Berni M, Mota J, Bressan D, Ribeiro L, Martins G, Pereira J, Ramos I, Nunes-da-Fonseca R, Araujo H. A pro-BMP function exerted by Rhodnius prolixus short gastrulation reveals great diversity in the role of BMP modulators during embryonic patterning. Open Biol 2023; 13:230023. [PMID: 37403495 DOI: 10.1098/rsob.230023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2023] Open
Abstract
Dorsal-ventral (DV) patterning is regulated by the bone morphogenetic pathway (BMP) in Bilateria. In insect DV patterning, the Toll pathway also plays a role, in addition to BMPs. Variations in the relative importance of each pathway for DV patterning have been reported using single species of coleopteran, hymenopteran, hemipteran and orthopteran insects. To investigate if the molecular control of DV patterning is conserved inside an insect order, the emergent model hemiptera species Rhodnius prolixus was studied. We found that R. prolixus BMP pathway controls the entire DV axis, with a broader effect respective to Toll, as shown for the hemiptera Oncopeltus fasciatus. Different from O. fasciatus, the unique R. prolixus short gastrulation (sog) and the twisted gastrulation (tsg) orthologues do not antagonize, but rather favour embryonic BMP signalling. Our results reinforce the hypothesis that hemiptera rely preferentially on BMPs for DV patterning but that, surprisingly, in R. prolixus Sog and Tsg proteins exert only a positive role to establish a dorsal-to-ventral BMP gradient. Since sog has been reported to be lost from orthopteran and hymenopteran genomes, our results indicate that Sog's role to modify BMP activity varies greatly in different insect species.
Collapse
Affiliation(s)
- M Berni
- Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular, Brazil (INCT-EM)
| | - J Mota
- Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- Post-graduate Program in Morphological Sciences (PCM), Federal University of Rio de Janeiro
| | - D Bressan
- Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - L Ribeiro
- Institute of Biodiversity and Sustainability (NUPEM), Federal University of Rio de Janeiro, Campus Macaé, Rio de Janeiro
| | - G Martins
- Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- Post-graduate Program in Morphological Sciences (PCM), Federal University of Rio de Janeiro
| | - J Pereira
- Institute for Medical Biochemistry, Federal University of Rio de Janeiro
| | - I Ramos
- Institute for Medical Biochemistry, Federal University of Rio de Janeiro
- Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular, Brazil (INCT-EM)
| | - R Nunes-da-Fonseca
- Institute of Biodiversity and Sustainability (NUPEM), Federal University of Rio de Janeiro, Campus Macaé, Rio de Janeiro
- Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular, Brazil (INCT-EM)
| | - H Araujo
- Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular, Brazil (INCT-EM)
| |
Collapse
|
6
|
Giraud S, Zamora JC, Zegers RGT, Bazin D, Ayyad Y, Bacca S, Beceiro-Novo S, Brown BA, Carls A, Chen J, Cortesi M, DeNudt M, Hagen G, Hultquist C, Maher C, Mittig W, Ndayisabye F, Noji S, Novario SJ, Pereira J, Rahman Z, Schmitt J, Serikow M, Sun LJ, Surbrook J, Watwood N, Wheeler T. β^{+} Gamow-Teller Strengths from Unstable ^{14}O via the (d,^{2}He) Reaction in Inverse Kinematics. Phys Rev Lett 2023; 130:232301. [PMID: 37354417 DOI: 10.1103/physrevlett.130.232301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 04/14/2023] [Accepted: 05/05/2023] [Indexed: 06/26/2023]
Abstract
For the first time, the (d,^{2}He) reaction was successfully used in inverse kinematics to extract the Gamow-Teller transition strength in the β^{+} direction from an unstable nucleus. The new technique was made possible by the use of an active-target time-projection chamber and a magnetic spectrometer, and opens a path to addressing a range of scientific challenges, including in astrophysics and neutrino physics. In this Letter, the nucleus studied was ^{14}O, and the Gamow-Teller transition strength to ^{14}N was extracted up to an excitation energy of 22 MeV. The data were compared to shell-model and state-of-the-art coupled-cluster calculations. Shell-model calculations reproduce the measured Gamow-Teller strength distribution up to about 15 MeV reasonably well, after the application of a phenomenological quenching factor. In a significant step forward to better understand this quenching, the coupled-cluster calculation reproduces the full strength distribution well without such quenching, owing to the large model space, the inclusion of strong correlations, and the coupling of the weak interaction to two nucleons through two-body currents.
Collapse
Affiliation(s)
- S Giraud
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J C Zamora
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - R G T Zegers
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Bazin
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Y Ayyad
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- IGFAE, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain
| | - S Bacca
- Institut für Kernphysik and PRISMA+ Cluster of Excellence, Johannes Gutenberg-Universität, 55128 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität Mainz, D-55099 Mainz, Germany
| | - S Beceiro-Novo
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- CITENI, Campus Industrial de Ferrol, Universidade da Coruña, Campus de Esteiro, 15403 Ferrol, Spain
| | - B A Brown
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Carls
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Chen
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - M Cortesi
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - M DeNudt
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - G Hagen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - C Hultquist
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Maher
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - W Mittig
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - F Ndayisabye
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Noji
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - S J Novario
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J Pereira
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - Z Rahman
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Schmitt
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Serikow
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L J Sun
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Surbrook
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Watwood
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Wheeler
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics: Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
7
|
Arora N, Lo M, Hanna NM, Pereira J, Digby G, Bechara R, Merchant SJ, Hopman W, Li S, Giles A, Chung W. Influence of a patient navigation program on timeliness of care in patients with esophageal cancer. Cancer Med 2023. [PMID: 37076968 DOI: 10.1002/cam4.5882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 03/06/2023] [Accepted: 03/19/2023] [Indexed: 04/21/2023] Open
Abstract
BACKGROUND Patient navigation (P.N.) is designed to eliminate barriers to care. The objective of this study was to evaluate the impact of a novel P.N. program on timeliness of care in patients with esophageal cancer. METHODS This retrospective study compared the timeliness of care for esophageal cancer patients before (January 2014-March 2018) and after the implementation of a novel P.N. program (April 2018-March 2020), called EDAP, at a tertiary care center. The primary outcome was time from biopsy to first treatment; secondary outcomes included time from biopsy to complete staging, biopsy to complete preoperative workup, and referral to the first point of contact. The outcomes were evaluated in the entire cohort and then in a subgroup of patients undergoing curative multimodality therapy. RESULTS There were 96 patients in the pre-EDAP group and 98 patients in the post-EDAP group. There was no significant difference between pre- and post-EDAP in the time from biopsy to first treatment and time from biopsy to staging in the overall cohort. In the subgroup of patients undergoing curative multimodality therapy, there was a significant decrease in time from biopsy to first treatment postnavigation (60-51 days, p = 0.02), in addition to a significant decrease in time from biopsy to preoperative workup and time from biopsy to staging. CONCLUSIONS This is the first study demonstrating that a novel P.N. program for patients with esophageal cancer improved timeliness of care. The group of patients who benefited most were those undergoing curative multimodality therapy, likely given the extensive coordination of services required by this group.
Collapse
Affiliation(s)
- Nikita Arora
- Division of General Surgery, Department of Surgery, Queen's University, Kingston, Ontario, Canada
| | - Marcus Lo
- School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada
| | - Nader M Hanna
- Division of General Surgery, Department of Surgery, Queen's University, Kingston, Ontario, Canada
| | - Jennifer Pereira
- Esophagogastric Diagnostic Assessment Program, Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada
| | - Geneviève Digby
- Division of Respirology, Department of Medicine, Queen's University, Kingston, Ontario, Canada
| | - Robert Bechara
- Division of Gastroenterology, Department of Medicine, Queen's University, Kingston, Ontario, Canada
| | - Shaila J Merchant
- Division of General Surgery, Department of Surgery, Queen's University, Kingston, Ontario, Canada
| | - Wilma Hopman
- Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| | - Shirley Li
- Kingston Health Sciences Center, Decision Support, Kingston, Ontario, Canada
| | - Andrew Giles
- Division of Thoracic Surgery, Department of Surgery, Queen's University, Kingston, Ontario, Canada
| | - Wiley Chung
- Division of Thoracic Surgery, Department of Surgery, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
8
|
Sallam I, Pereira J, Amira G, Downey S, Down S, Leeper A, El Ayyan R. P239 Multi-institutional Experience of Modified Lateral Intercostal Artery Perforator (LICAP) Flap Operation: Surgical and Patient Reported Outcomes (PROMs). Breast 2023. [DOI: 10.1016/s0960-9776(23)00357-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
|
9
|
Koppiker C, Kelkar D, Kulkarni M, Pai M, Dhar U, Deshmukh C, Varghese B, Jumle N, Zamre V, Kadu S, Joshi A, Unde R, Banale R, Namewar N, Vaid P, Thomas G, Nare S, Pereira J, Badve S. P225 Impact Of Oncoplasty in Increasing Breast Conservation Rates Post Neo-Adjuvant Chemotherapy. Breast 2023. [DOI: 10.1016/s0960-9776(23)00343-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
|
10
|
Zhang T, Pereira J, Sasikumar S, Barber PA. Upper cervical cord infarction: a rare and tragic case. Intern Med J 2023; 53:443-444. [PMID: 36972993 DOI: 10.1111/imj.16030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 12/09/2022] [Indexed: 03/29/2023]
Affiliation(s)
- Tony Zhang
- Department of Neurology, Auckland City Hospital, Auckland, New Zealand
| | - Jennifer Pereira
- Department of Neurology, Auckland City Hospital, Auckland, New Zealand
| | | | - Peter A Barber
- Department of Neurology, Auckland City Hospital, Auckland, New Zealand
| |
Collapse
|
11
|
Vieira e Brito D, Fereira A, Pereira J, Pereira-Lourenço M, Godinho R, Pereira B, Peralta P, Conceiçao P, Reis Mario A, Paula Rabaça C. Impacto de la realización de RMmp antes de la braquiterapia en pacientes con cáncer de próstata. Actas Urol Esp 2023. [DOI: 10.1016/j.acuro.2023.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
12
|
Cortesi M, Dziubinski S, Gade A, Zegers R, Pereira J, Asciutto J, Lidia S, Bazin D. Design and construction of a novel energy-loss optical scintillation system (ELOSS) for heavy-ion particle identification. Rev Sci Instrum 2022; 93:123305. [PMID: 36586929 DOI: 10.1063/5.0124846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 11/18/2022] [Indexed: 06/17/2023]
Abstract
We present the development of a novel heavy-ion particle-identification (PID) device based on an energy-loss measurement to be implemented in the focal plane of the S800 spectrograph of the Facility for Rare Isotope Beams (FRIB). The new instrument consists of a multi-segmented optical detector [energy-loss optical scintillation system (ELOSS)] that is filled with xenon at pressures ranging from 400 to 800 Torr. The gas volume is surrounded by arrays of photomultiplier tubes and placed along the direction of the beam for recording the prompt scintillation light. The number of detected photons, which is proportional to the energy deposited by the beam particle along its track in the detector volume, allows one to identify the corresponding atomic number (Z). The ELOSS technology is expected to provide high-resolution ΔE measurements (≤0.6% σ) at a high counting rate (>50 kHz). In addition, it has the capability of providing timing information with around 150 ps resolution (σ) compared to the lack of useable timing information of the conventional ionization chamber relying on drifting charges. The development of fast, accurate ΔE measurement techniques for present and future nuclear science facilities will have a high impact on the design and implementation of rare-isotope beam experiments at FRIB and their scientific outcome. As such, ELOSS also represents a prototype for the development of PID detector systems of other planned and future spectrometers, such as the high rigidity spectrometer at FRIB.
Collapse
Affiliation(s)
- M Cortesi
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Dziubinski
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Gade
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - R Zegers
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Pereira
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Asciutto
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Lidia
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Bazin
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
13
|
Oliveira A, Pereira J, Sarmento S, Pereira M, Cardoso J, Santos L, Alves J, Santos J. Study on the dose profile in CT-fluoroscopy. Appl Radiat Isot 2022; 190:110516. [DOI: 10.1016/j.apradiso.2022.110516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 10/03/2022] [Accepted: 10/12/2022] [Indexed: 11/02/2022]
|
14
|
Lage LAPC, Soares VA, Meneguin TD, Culler HF, Reichert CO, Costa RO, Reis DGC, Zerbini MCN, Rocha V, Pereira J. WHOLE BRAIN RADIOTHERAPY IS AN EFFECTIVE AND SAFE STRATEGY TO CONSOLIDATE PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS IN MIDDLE-INCOME COUNTRIES: A REAL-LIFE EXPERIENCE FROM BRAZIL. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
15
|
Chiattone C, Miranda E, Gonzaga Y, Dias M, Salvino MA, Baptista RLR, Bortucchi D, Christofoletti T, Duffles G, Bellesso M, Pereira J, Brasil SAB, Castro NS, Cecyn KZ, Schaffel R, Tavares JV, Figueiredo VLP, Nogueira FL, Silva NAHL, Silva GF, Cunha-Junior AD, Gaiolla R, Duarte FB, Souza RR, Hallack-Neto A, Cordeiro A, Rabelo YS, Delamain MT, Federico M, Souza CA. A PREVENÇÃO DEVE SER A MELHOR ESTRATÉGIA PARA ENFRENTAR A LEUCEMIA/LINFOMA DE CÉLULAS-T DE ADULTO DO PROJETO T-CELL BRASIL. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
16
|
Lage LAPC, Barreto GC, Culler HF, Cavalcanti JB, Reichert CO, Levy D, Costa RO, Zerbini MCN, Rocha V, Pereira J. HIGH TUMOR MUTATION BURDEN IN EPIGENETIC REGULATORY GENES PREDICTS DECREASED OVERALL SURVIVAL IN NODAL PERIPHERAL T-CELL LYMPHOMAS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
17
|
Lage LAPC, Vita RN, Alves LBO, Jacomassi MD, Culler HF, Reichert CO, Costa RO, Siqueira SAC, Rocha V, Pereira J. AGE 75 YEARS, CLINICAL STAGE III/IV, NEUTROPHILIA AND HIGH LYMPHOCYTE/MONOCYTE RATIO PREDICT DECREASED OVERALL SURVIVAL IN ELDERLY PATIENTS WITH DLBCL, NOS OLDER THAN 70 YEARS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
18
|
Marques KS, Pereira J, Casseb JSDR, Rocha VG, Nukui Y. PERFIL DE PACIENTES COM HTLV-1, PREVALÊNCIA DE ATLL E A RELAÇÃO DA VIA PERINATAL/AMAMENTAÇÃO COMO A PRINCIPAL PARA TRANSMISSÃO VIRAL EM PACIENTES COM ATLL ACOMPANHADOS NO AMBULATÓRIO DE HTLV DA DISCIPLINA DE HEMATOLOGIA E HEMOTERAPIA DO HCFMUSP. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
19
|
Chiattone CS, Miranda E, Pereira J, Cecyn KZ, Castro NS, Brasil SAB, Farias DFC, Bellesso M, Duffles G, Borducchi D, Gonzaga Y, Baptista RLR, Vilarim CC, Macedo CCG, Dias M, Salvino MA, Tavares JV, Nabhan S, Cunha-Junior AD, Zing N, Silva GF, Ribeiro GN, Negreiros E, Schaffel R, Figueiredo VLP, Souto-Filho JTD, Radtke PPG, Pont MD, Nogueira FL, Hamerschlak N, Cle DV, Gaiolla R, Duarte FB, Souza RR, Mo S, Hallack-Neto A, Rabelo YS, Ribeiro EFO, Cordeiro A, Perini G, Bueno ND, Matedi MAL, Cury P, Delamain MT, Federico M, Souza CA. PROJETO T-CELL BRASIL: ATUALIZAÇÃO DO PROJETO PIONEIRO DE COLETA DE DADOS DE PACIENTES COM LNH DE CÉLULAS T NAS CINCO REGIÕES BRASILEIRAS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
20
|
Silva CA, Pereira J, Rego EM, Rocha V, Silva WF. RISK FACTORS FOR ACUTE KIDNEY INJURY IN OUTPATIENT ADMINISTRATION OF HIGH-DOSE METHOTREXATE IN ADULTS WITHOUT DRUG MONITORING. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
21
|
Lage LAPC, Machado PPF, Reichert CO, Miranda E, Culler HF, Souza CA, Federico M, Rocha V, Pereira J, Chiattone CS. CLINICAL OUTCOMES, PROGNOSTIC FACTORS AND THERAPEUTIC MANAGEMENT IN EXTRANODAL NATURAL-KILLER/T-CELL LYMPHOMA, NASAL-TYPE (ENKTL-NT) – RESULTS OF THE MULTICENTER T-CELL BRAZIL PROJECT. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
22
|
Goralczyk A, Pereira J, Torres LO, Iskandar A, van der Toor M, Talikka M, Luettich K, Marescotti D. P01-02 AOP-based in vitro assay development for assessment of inhalational toxicants — oxidative stress leading to decreased lung function. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Pereira J, Durairaj J, Pantolini L, Studer G, Robin X, Waterhouse A, Bienert S, Tauriello G, Schwede T. How predicted protein models help to illuminate the full protein universe. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322096024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
24
|
Ayyad Y, Mittig W, Tang T, Olaizola B, Potel G, Rijal N, Watwood N, Alvarez-Pol H, Bazin D, Caamaño M, Chen J, Cortesi M, Fernández-Domínguez B, Giraud S, Gueye P, Heinitz S, Jain R, Kay BP, Maugeri EA, Monteagudo B, Ndayisabye F, Paneru SN, Pereira J, Rubino E, Santamaria C, Schumann D, Surbrook J, Wagner L, Zamora JC, Zelevinsky V. Evidence of a Near-Threshold Resonance in ^{11}B Relevant to the β-Delayed Proton Emission of ^{11}Be. Phys Rev Lett 2022; 129:012501. [PMID: 35841541 DOI: 10.1103/physrevlett.129.012501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 04/29/2022] [Accepted: 06/01/2022] [Indexed: 06/15/2023]
Abstract
A narrow near-threshold proton-emitting resonance (E_{x}=11.4 MeV, J^{π}=1/2^{+}, and Γ_{p}=4.4 keV) was directly observed in ^{11}B via proton resonance scattering. This resonance was previously inferred in the β-delayed proton emission of the neutron halo nucleus ^{11}Be. The good agreement between both experimental results serves as a ground to confirm the existence of such exotic decay and the particular behavior of weakly bound nuclei coupled to the continuum. R-matrix analysis shows a sizable partial decay width for both, proton and α (Γ_{α}=11 keV) emission channels.
Collapse
Affiliation(s)
- Y Ayyad
- IGFAE, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - W Mittig
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Tang
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - B Olaizola
- ISOLDE-EP, CERN, CH-1211 Geneva 23, Switzerland
| | - G Potel
- Lawrence Livermore National Lab., P.O. Box 808, Livermore, California 94550, USA
| | - N Rijal
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Watwood
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - H Alvarez-Pol
- IGFAE, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain
| | - D Bazin
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Caamaño
- IGFAE, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain
| | - J Chen
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Cortesi
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - B Fernández-Domínguez
- IGFAE, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain
| | - S Giraud
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - P Gueye
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Heinitz
- Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen PSI, Switzerland
| | - R Jain
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - B P Kay
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - E A Maugeri
- Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen PSI, Switzerland
| | - B Monteagudo
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - F Ndayisabye
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S N Paneru
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Pereira
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - E Rubino
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Santamaria
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Schumann
- Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen PSI, Switzerland
| | - J Surbrook
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L Wagner
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - J C Zamora
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - V Zelevinsky
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
25
|
Santos H, Dornelles E, Pereira J, Vieira A. What is the Pisa Syndrome? A review. Eur Psychiatry 2022. [PMCID: PMC9567206 DOI: 10.1192/j.eurpsy.2022.1872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction
Pisa syndrome (PS) is a type of dystonia of rare occurrence, first described in 1972 as an adverse effect of neuroleptic agents. It is used to describe a postural abnormality that includes trunk flexion in the coronal plane and axial rotation, which improves in the supine position.
Objectives
In this work, we aim to conduct a brief review of Pisa Syndrome aetiology, pathophysiology and treatment.
Methods
A non-systematic search was conducted through the PubMed database for “pisa syndrome”. Articles were screened for relevant information on PS aetiology, pathophysiology and treatment.
Results
Pisa syndrome has been associated as an adverse effect of multiple drugs from different classes, mainly antipsychotics, dopaminergic agents and cholinesterase inhibitors. The underlying mechanisms are not yet fully understood. Nevertheless, one of the most consensual hypothesis considers PS as a consequence of a cholinergic-dopaminergic imbalance that can be caused by antipsychotic treatment. Some factors have been associated with increased risk for developing PS such as old age and polypharmacy. PS appears to be better treated with the reduction or interruption of the agent(s) associated with its onset.
Conclusions
Despite its low incidence, Pisa syndrome can occur as a side effect of a number of different medications and the identification of the trigger-drug is fundamental so it can be reduced or interrupted in order to treat this condition.
Disclosure
No significant relationships.
Collapse
|
26
|
Vasques A, Baleiras M, Ferreira A, Duarte T, Branco V, Pereira J, Lobo-Martins S, Pinto M, Martins A. P-59 Real-world data of trastuzumab in metastatic cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
27
|
Quinchard G, Poletti T, Zakhama R, Pereira J, Larrue A, Badano G, Licitra C, de Lamaestre RE, Reverchon JL, Delga A. Revisiting the Fabry-Perot reflectivity method for mid-infrared optical index measurement: case study of InGaAs, AlInAs, and InP. Appl Opt 2022; 61:4079-4086. [PMID: 36256083 DOI: 10.1364/ao.456827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 04/19/2022] [Indexed: 06/16/2023]
Abstract
We revisit the Fabry-Perot (FP) reflectivity method to measure optical indices in the mid-infrared spectrum. This simple approach can be readily implemented using a standard Fourier transform infrared spectrometer. Measuring samples with multiple heights allows for enhanced precision of the measurement, making the FP method consistent in values and uncertainties with more advanced ellipsometric measurements. An extensive discussion about experimental errors is carried out. Results between 4 and 12 µm for AlInAs, n-doped InGaAs, and InP, which are the most standard materials for quantum cascade lasers, are given.
Collapse
|
28
|
Braga S, Barreto J, Torgal A, Pereira J, Leão A, Gonçalves N, Araújo L. T170 Three cases of endocrine immune-related adverse events caused by immune checkpoint inhibitor therapy. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Bühning F, Miguel Telega L, Tong Y, Pereira J, Coenen V, Döbrössy M. Electrophysiological and molecular effects of bilateral deep brain stimulation of the medial forebrain bundle in a rodent model of depression. Exp Neurol 2022; 355:114122. [DOI: 10.1016/j.expneurol.2022.114122] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 05/10/2022] [Accepted: 05/18/2022] [Indexed: 11/04/2022]
|
30
|
Clarke L, Bukhari W, O'Gorman CM, Khalilidehkordi E, Arnett S, Woodhall M, Prain KM, Parratt JDE, Barnett MH, Marriott MP, McCombe PA, Sutton I, Boggild M, Brownlee W, Carroll WM, Hodgkinson S, Macdonell RAL, Mason DF, Pereira J, Slee M, Das C, Henderson APD, Kermode AG, Lechner-Scott J, Waters P, Sun J, Broadley SA. Response to treatment in NMOSD: the Australasian experience. Mult Scler Relat Disord 2022; 58:103408. [PMID: 35216788 DOI: 10.1016/j.msard.2021.103408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 11/09/2021] [Accepted: 11/14/2021] [Indexed: 11/24/2022]
Abstract
BACKGROUND Neuromyelitis optica spectrum disorder (NMOSD) is associated with significant morbidity and mortality. Several therapies have been recommended for NMOSD and more recently clinical trials have demonstrated efficacy for three monoclonal antibody therapies. We present a retrospective observational study of treatment response in NMOSD. METHODS This was a retrospective, unblinded, observational study of treatment efficacy for rituximab and traditional immunosuppressive therapy in patients with AQP4 antibody positive NMOSD. Treatment efficacy was assessed using annualised relapse rates (ARR), time to first relapse and expanded disability status scale (EDSS) scores. RESULTS Complete relapse and treatment data were available for 43/68 (63%) of AQP4 antibody positive NMOSD cases covering 74 episodes of treatment. In a time to first relapse analysis rituximab showed a risk ratio of 0.23 (95% CI 0.08 - 0.65) when compared with no treatment and there was a non-significant reduction in ARR of 35% compared to pre-treatment. β-interferon (p = 0.0002) and cyclophosphamide (p = 0.0034) were associated with an increased ARR compared to pre-treatment. Rituximab (median 4.0 [range 0.0 - 7.0]; p = 0.042) and traditional immunosuppressive therapy (median 4.0 [range 0.0 - 8.0]; p = 0.016) were associated with a lower final EDSS compared to β-interferon (median 6.0 [range 4.0 - 7.5]). CONCLUSIONS These data provide additional support for the use of rituximab in preference to traditional immunosuppressive agents and MS disease modifying therapies as first line treatment of NMOSD.
Collapse
Affiliation(s)
- Laura Clarke
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; Department of Neurology Princess Alexandra Hospital, Woolloongabba QLD 4102, Australia
| | - Wajih Bukhari
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; St Vincent's Hospital Melbourne, Fitzroy VIC 3065, AustraliA
| | - Cullen M O'Gorman
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; Department of Neurology Princess Alexandra Hospital, Woolloongabba QLD 4102, Australia; Department of Neurology, Mater Hospital Brisbane, South Brisbane QLD, 4101, Australia
| | - Elham Khalilidehkordi
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; Department of Neurology, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia
| | - Simon Arnett
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; Department of Neurology, Gold Coast University Hospital, Southport QLD 4215, Australia
| | - Mark Woodhall
- Nuffield Department of Clinical Neurosciences, John Radcliffe Infirmary, University of Oxford, Oxford OX3 9DU, UK
| | - Kerri M Prain
- Department of Immunology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4006, Australia
| | - John D E Parratt
- Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown NSW 2006, Australia
| | - Michael H Barnett
- Brain and Mind Research Institute, University of Sydney, Camperdown NSW 2006, Australia
| | - Mark P Marriott
- Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville VIC 3052, Australia
| | - Pamela A McCombe
- Department of Neurology, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia; Centre for Clinical Research, Royal Brisbane and Women's Hospital, University of Queensland, Herston QLD 4029, AustraliA
| | - Ian Sutton
- Department of Neurology, St Vincent's Hospital, Darlinghurst NSW 2010, Australia
| | - Mike Boggild
- Department of Neurology, Townsville Hospital, Douglas QLD 4814, Australia
| | - Wallace Brownlee
- Department of Neurology, Auckland City Hospital, Grafton 1023, New Zealand; Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
| | - William M Carroll
- Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, Queen Elizabeth II Medical Centre, University of Western Australia, Nedlands WA 6009, AustraliA
| | - Suzanne Hodgkinson
- South Western Sydney Medical School, Liverpool Hospital, University of New South Wales, Liverpool NSW 2170, Australia
| | | | - Deborah F Mason
- Department of Neurology, Christchurch Hospital, Christchurch 8140, New Zealand
| | - Jennifer Pereira
- Department of Neurology, Auckland City Hospital, Grafton 1023, New Zealand
| | - Mark Slee
- Flinders Medical Centre, Flinders University, Bedford Park SA 5042, Australia
| | - Chandi Das
- Department of Neurology, Canberra Hospital, Garran ACT 2605, Australia
| | | | - Allan G Kermode
- Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, Queen Elizabeth II Medical Centre, University of Western Australia, Nedlands WA 6009, AustraliA; Institute for Immunology and Infectious Disease, Murdoch University, Murdoch WA 6150, AustraliA
| | - Jeannette Lechner-Scott
- Hunter Medical Research Institute, University of Newcastle, New Lambton Heights NSW 2305, AustralIA
| | | | - Patrick Waters
- Department of Neurology, Gold Coast University Hospital, Southport QLD 4215, Australia
| | - Jing Sun
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia
| | - Simon A Broadley
- Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; Department of Neurology, Gold Coast University Hospital, Southport QLD 4215, Australia.
| |
Collapse
|
31
|
Catarino R, Alves L, Pereira J, Pereira D, Costa G, Cardoso A, Braga I, Freitas R, Correia T, Cerqueira M, Carmo Reis F, Lobo F, Morais A, Silva V, Magalhães S, Prisco R. Neoadjuvant chemotherapy in patients with urothelial bladder cancer. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03227-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
32
|
Silva C, Ferrao D, Soares P, Nogueira F, Oliveira D, Ferreira A, Silva J, Lume M, Melo N, Pereira J, Araujo J, Lourenco P. The monocyte/high-density lipoprotein ratio predicts coronary artery disease in heart failure. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The monocyte/high density lipoprotein ratio (MHR) is a combined inflammatory marker implicated in atherosclerosis. MHR predicts cerebrovascular disease (CVD) and chronic kidney disease (CKD); it correlates with coronary artery disease (CAD) severity and has been shown to be a prognostic predictor in patients with myocardial infarction. The role of MHR in chronic heart failure (HF) is largely unknown.
Purpose
Assess the ability of MHR to predict CAD in patients with HF
Methods
We conducted a retrospective cohort study in ambulatory patients with HF with left ventricular systolic dysfunction (LVSD) that were followed in our HF clinic from January/2012 to May/2018. We selected all the patients that had performed a diagnostic/therapeutic coronary angiography. Patients with missing data concerning monocyte counts or high-density lipoprotein levels were excluded. The endpoint under analysis was the presence of CAD on coronary angiography. A ROC curve was used to study the ability of MHR to predict CAD. The association of MHR with CAD was assessed by a logistic-regression analysis. A multivariate model was built accounting for age, sex, comorbidities [hypertension, diabetes, peripheral artery disease (PAD), CVD, CKD and inflammatory/auto-immune disease], low-density lipoprotein value, haemoglobin, brain-type natriuretic peptide (BNP), severe LVSD and segmental contractility defects in the echocardiogram. MHR was analysed both as continuous and categorical variable; the cut-off of 16 was chosen based on the ROC curve.
Results
We studied 295 chronic HF patients with LSVD who underwent coronary angiography. Mean age was 67±12 years, 70.8% men and 55.9% with CAD. Patients with CAD were older (69 against 64 years), had significantly higher MHR (19±9 vs. 16±7), higher prevalence of hypertension, diabetes, PAD and CVD, and worse renal function. The area under the curve for the association between MHR and CAD was 0.68 (0.62–0.74), p<0.001. The best MHR cut-off for CAD prediction was 16 - sensitivity: 66.7%, specificity: 65.4%, positive predictive value: 71.0% and negative predictive value: 60.8%. This association was independent of potential confounders. Patients with MHR≥16 had a multivariate-adjusted OR of having CAD of 5.41 (95% CI: 2.40–12.20), p<0.001 when compared to those with lower MHR. When MHR was analysed as a continuous variable the association remained significant.
Conclusions
The MHR is an independent predictor of CAD in chronic HF. Patients with MHR ≥16 have a 71% probability of presenting CAD and a more than 5-fold higher risk compared with those with lower MHR. It is sometimes difficult to ascertain ischemic disease/aetiology in HF patients, particularly in the elderly, frail and/or with advanced CKD. This simple, inexpensive and harmless marker can help clinicians identify patients most likely to have CAD and decide treatment in accordance.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- C.M Silva
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - D Ferrao
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - P.R Soares
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - F Nogueira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - D.M Oliveira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - A.I Ferreira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - J.E Silva
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - M.J Lume
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - N Melo
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - J Pereira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - J.P Araujo
- Centro Hospitalar Universitario Sao Joao, Heart Failure Clinic of the Internal Medicine Department, Porto, Portugal
| | - P Lourenco
- Centro Hospitalar Universitario Sao Joao, Heart Failure Clinic of the Internal Medicine Department, Porto, Portugal
| |
Collapse
|
33
|
Silva C, Ferrao D, Soares P, Nogueira F, Oliveira D, Ferreira A, Silva J, Lume M, Melo N, Pereira J, Lourenco P, Araujo J. The prognostic value of monocyte/ high-density lipoprotein ratio in chronic heart failure. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The monocyte-high density lipoprotein ratio (MHR) is an inflammation marker that combines monocyte counts, increased in inflammatory states, and high-density lipoprotein (HDL) levels, that appear to have protective and anti-inflammatory properties. It has been studied in chronic kidney disease, primary hypertension, cerebrovascular disease and coronary artery disease (CAD), and has been shown to be positively correlated with disease severity and worse prognosis. Although inflammation is thought to be implicated in heart failure's (HF) pathophysiology, little is known about the role of MHR in the HF setting.
Purpose
To study the prognostic impact of MHR in chronic HF.
Methods
We conducted a retrospective cohort study in ambulatory patients with HF with left ventricular systolic dysfunction (LVSD) that were followed in our HF clinic from January/2012 to May/2018. Patients with no data on monocyte counts or HDL levels in the first appointment were excluded. Endpoint under analysis: all-cause mortality. Patients were categorized according to MHR quartiles: 1st quartile <11, 2nd quartile ≥11 to <15, 3rd quartile ≥15 to <20 and 4th quartile ≥20. A Cox-regression analysis was used to assess association between MHR and all-cause mortality. A multivariate model was built adjusting for age, sex, hypertension, diabetes mellitus (DM), CAD, obstructive sleep apnea, inflammatory/autoimmune disease, atrial fibrillation, anaemia, renal dysfunction, brain-type-natriuretic peptide (BNP), New York Heart Association (NYHA) class, low-density lipoprotein value, prognostic modifying therapy and severe LVSD.
Results
We studied 560 chronic HF patients with LVSD, mean age 70±12 years, 67.5% men, 37.1% in NYHA class I, 44.8% in NYHA class II and the remaining in higher classes. Patients with MHR≥20 (last quartile) were mostly men with higher prevalence of DM and CAD, they more often presented in higher NYHA classes and with worse renal function and higher BNP. No difference existed concerning doses of evidence based-drugs. During a median follow-up of 53 (32–88) months from the index medical appointment 256 patients (45.7%) died. Mortality was similar in the lower three MHR quartiles, being statistically higher in the last quartile. Considering only two groups - MHR <20 and MHR ≥20 - the all-cause mortality rate was of 41.6 vs. 57.6%, respectively, p=0,001. MHR was independently associated with poor survival. In patients presenting with MHR ≥20, the HR of long-term all-cause mortality was 1.42 (95% CI: 1.04–1.93), p=0.03 when compared with those with lower MHR.
Conclusions
Chronic HF patients with MHR ≥20 have a significant 42% increased risk of long-term all-cause death. We reinforce the role of inflammation in chronic HF. The MHR is a practical, inexpensive and widely available parameter that can help clinicians in the identification of chronic HF patients at higher risk of death.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- C.M Silva
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - D Ferrao
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - P.R Soares
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - F Nogueira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - D.M Oliveira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - A.I Ferreira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - J.E Silva
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - M.J Lume
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - N Melo
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - J Pereira
- Centro Hospitalar Universitario Sao Joao, Internal Medicine, Porto, Portugal
| | - P Lourenco
- Centro Hospitalar Universitario Sao Joao, Heart Failure Clinic of the Internal Medicine Department, Porto, Portugal
| | - J.P Araujo
- Centro Hospitalar Universitario Sao Joao, Heart Failure Clinic of the Internal Medicine Department, Porto, Portugal
| |
Collapse
|
34
|
Oliveira KS, Culler HF, Levy D, Filho JRA, Nogueira D, Silva LH, Fonseca FLA, Alves SIPMDN, Lage LAPC, Pereira J. CIRCULATING CELL-FREE DNA (CCFDNA) ISOLATION FROM PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMPARATIVE ANALYSIS OF COMMERCIAL KITS. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Lima GGM, Machado PPF, Castelo LF, Rocha V, Lage LAPC, Pereira J. ERDHEIM-CHESTER DISEASE (ECD): A RARE ETIOLOGY OF OBSTRUCTIVE ACUTE ABDOMEN IN A YOUNG PATIENT. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
36
|
Lage LAPC, Brito CV, Barreto GC, Reichert CO, Levy D, Culler HF, Zerbini MCN, Rocha V, Pereira J. HIGH TOXICITY AND POOR SURVIVAL WITH ASSOCIATION CHOP PLUS ETOPOSIDE COMPARED TO CHOP REGIMEN IN 124 BRAZILIAN PATIENTS WITH NODAL PTCL LYMPHOMAS (NPTCL): A REAL-LIFE EXPERIENCE. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
37
|
Machado PPF, Lima GGM, Castelo LF, Rocha V, Lage LAPC, Pereira J. SARCOMATOID DIFFUSE LARGE B-CELL LYMPHOMA: A RARE MORPHOLOGICAL VARIANT WITH MULTI-VISCERAL INVOLVEMENT. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
38
|
Catarino R, Alves L, Costa G, Pereira D, Pereira J, Cardoso A, Braga I, Freitas R, Correia T, Cerqueira M, Carmo Reis F, Lobo F, Morais A, Prisco R. Neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)01229-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
39
|
Kayano AE, Vita RN, Zambrana MAA, Brandão AAGS, Abdo ANR, Rocha VG, Pereira J. ERDHEIM-CHESTER ATÍPICO: UM RELATO DE CASO. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
40
|
Chiattone CS, Delamain MT, Miranda ECM, Pereira J, Farias DLC, Nabhan S, Bellesso M, Hamerschlak N, Zing N, Castro N, Ribeiro G, Baptista RLR, Gonzaga Y, Gaiolla R, Cordeiro A, Schaffel R, Souto-Filho JTD, Negreiros E, Hallack-Neto A, Ribeiro EFO, Vilarim CC, Macedo CCG, Brasil SAB, Mo SKG, Cunha-Junior AD, Cury P, Cecyn KZ, Duffles G, Federico M, Souza CA. O PAPEL DO TRANSPLANTE NOS LINFOMAS DE CÉLULAS T: DADOS PRELIMINARES DO PROJETO T-CELL BRASIL. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
41
|
Lage LAPC, Barreto GC, Culler HF, Cavalcanti JB, Alves LBO, Nardinelli L, Bendit I, Rocha V, Pereira J. RHOA MUTATION IS A POTENTIAL BIOMARKER ASSOCIATED WITH ADVERSE PROGNOSIS AND HIGH- TUMOR BURDEN IN PATIENTS WITH NODAL PERIPHERAL LYMPHOMAS WITH T-HELPER FOLLICULAR PHENOTYPE (NPTCL-THF): DATA FROM A BRAZILIAN RETROSPECTIVE COHORT OF NPTCL. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
42
|
Rothschild C, Sabanai AH, Santos AAD, Sousa CO, Siqueira RS, Neves TRVF, Brandão AAGS, Diz MDPE, Pereira J, Rocha V. PHARMACEUTICAL VIGILANCE AND EDUCATION: THE FIRST 6 MONTHS OF A NEW ANTICOAGULANT AT A BRAZILIAN PUBLIC CANCER INSTITUTE. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
43
|
Castelo LF, Silva DLF, Lima GGM, Machado PPF, Rocha V, Lage LAPC, Pereira J. HYPEREOSINOPHILIA, MYELOPHITISIS AND CUTANEOUS METASTASES: ATYPICAL PRESENTATION OF NON-SMALL CELL LUNG CARCINOMA. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
44
|
Rothschild C, Nedachi NL, Rabelo AP, Souza PR, Faria GBG, Silva MR, Brandão AAGS, Diz MDPE, Pereira J, Rocha V. RECOMMENDATION ON THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS AT A BRAZILIAN PUBLIC ONCOLOGICAL INSTITUTION: EDUCATIONAL PLAN. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
45
|
Clarke L, Arnett S, Bukhari W, Khalilidehkordi E, Jimenez Sanchez S, O'Gorman C, Sun J, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Abernethy DA, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Fabis-Pedrini MJ, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Ramanathan S, Reddel SW, Shaw CP, Spies JM, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AGK, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Brilot F, Vincent A, Waters P, Broadley SA. MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Front Neurol 2021; 12:722237. [PMID: 34566866 PMCID: PMC8458658 DOI: 10.3389/fneur.2021.722237] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 08/10/2021] [Indexed: 01/01/2023] Open
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the CNS. Overlap in the clinical and MRI features of NMOSD and MS means that distinguishing these conditions can be difficult. With the aim of evaluating the diagnostic utility of MRI features in distinguishing NMOSD from MS, we have conducted a cross-sectional analysis of imaging data and developed predictive models to distinguish the two conditions. NMOSD and MS MRI lesions were identified and defined through a literature search. Aquaporin-4 (AQP4) antibody positive NMOSD cases and age- and sex-matched MS cases were collected. MRI of orbits, brain and spine were reported by at least two blinded reviewers. MRI brain or spine was available for 166/168 (99%) of cases. Longitudinally extensive (OR = 203), "bright spotty" (OR = 93.8), whole (axial; OR = 57.8) or gadolinium (Gd) enhancing (OR = 28.6) spinal cord lesions, bilateral (OR = 31.3) or Gd-enhancing (OR = 15.4) optic nerve lesions, and nucleus tractus solitarius (OR = 19.2), periaqueductal (OR = 16.8) or hypothalamic (OR = 7.2) brain lesions were associated with NMOSD. Ovoid (OR = 0.029), Dawson's fingers (OR = 0.031), pyramidal corpus callosum (OR = 0.058), periventricular (OR = 0.136), temporal lobe (OR = 0.137) and T1 black holes (OR = 0.154) brain lesions were associated with MS. A score-based algorithm and a decision tree determined by machine learning accurately predicted more than 85% of both diagnoses using first available imaging alone. We have confirmed NMOSD and MS specific MRI features and combined these in predictive models that can accurately identify more than 85% of cases as either AQP4 seropositive NMOSD or MS.
Collapse
Affiliation(s)
- Laura Clarke
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Simon Arnett
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Wajih Bukhari
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Elham Khalilidehkordi
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Sofia Jimenez Sanchez
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Cullen O'Gorman
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Jing Sun
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Kerri M Prain
- Department of Immunology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - Mark Woodhall
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
| | - Roger Silvestrini
- Department of Immunopathology, Westmead Hospital, Westmead, NSW, Australia
| | - Christine S Bundell
- School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, WA, Australia
| | | | - Sandeep Bhuta
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Stefan Blum
- Department of Neurology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Mike Boggild
- Department of Neurology, Townsville Hospital, Douglas, QLD, Australia
| | - Karyn Boundy
- Department of Neurology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia
| | - Bruce J Brew
- Centre for Applied Medical Research, St. Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia
| | - Wallace Brownlee
- Department of Neurology, Auckland City Hospital, Grafton, New Zealand
| | - Helmut Butzkueven
- Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia
| | - William M Carroll
- Centre for Neuromuscular and Neurological Disorders, Queen Elizabeth II Medical Centre, Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, WA, Australia
| | - Cella Chen
- Department of Ophthalmology, Flinders Medical Centre, Flinders University, Bedford Park, SA, Australia
| | - Alan Coulthard
- School of Medicine, Royal Brisbane and Women's Hospital, University of Queensland, Herston, QLD, Australia
| | - Russell C Dale
- Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia
| | - Chandi Das
- Department of Neurology, Canberra Hospital, Garran, ACT, Australia
| | - Marzena J Fabis-Pedrini
- Centre for Neuromuscular and Neurological Disorders, Queen Elizabeth II Medical Centre, Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, WA, Australia
| | - David Gillis
- School of Medicine, Royal Brisbane and Women's Hospital, University of Queensland, Herston, QLD, Australia
| | - Simon Hawke
- Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia
| | - Robert Heard
- Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia
| | | | - Saman Heshmat
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia
| | - Suzanne Hodgkinson
- South Western Sydney Medical School, Liverpool Hospital, University of New South Wales, Liverpool, NSW, Australia
| | - Trevor J Kilpatrick
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
| | - John King
- Department of Neurology, Royal Melbourne Hospital, Parkville, VIC, Australia
| | | | - Andrew J Kornberg
- School of Paediatrics, Royal Children's Hospital, University of Melbourne, Parkville, VIC, Australia
| | - Jeannette Lechner-Scott
- Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW, Australia
| | - Ming-Wei Lin
- Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia
| | | | | | - Deborah F Mason
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| | - Pamela A McCombe
- Centre for Clinical Research, Royal Brisbane and Women's Hospital, University of Queensland, Herston, QLD, Australia
| | - Jennifer Pereira
- School of Medicine, University of Auckland, Grafton, New Zealand
| | - John D Pollard
- Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia
| | - Sudarshini Ramanathan
- Neuroimmunology Group, Kids Neurosciences Centre, Children's Hospital at Westmead, University of Sydney, Westmead, NSW, Australia.,Department of Neurology, Concord Repatriation General Hospital, Concord, NSW, Australia
| | - Stephen W Reddel
- Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia
| | - Cameron P Shaw
- School of Medicine, Deakin University, Waurn Ponds, VIC, Australia
| | - Judith M Spies
- Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia
| | - James Stankovich
- Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia
| | - Ian Sutton
- Department of Neurology, St. Vincent's Hospital, Darlinghurst, NSW, Australia
| | - Steve Vucic
- Department of Neurology, Westmead Hospital, Westmead, NSW, Australia
| | - Michael Walsh
- Department of Neurology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Richard C Wong
- School of Medicine, Royal Brisbane and Women's Hospital, University of Queensland, Herston, QLD, Australia
| | - Eppie M Yiu
- School of Paediatrics, Royal Children's Hospital, University of Melbourne, Parkville, VIC, Australia
| | - Michael H Barnett
- Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia
| | - Allan G K Kermode
- Centre for Neuromuscular and Neurological Disorders, Queen Elizabeth II Medical Centre, Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, WA, Australia
| | - Mark P Marriott
- Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia
| | - John D E Parratt
- Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia
| | - Mark Slee
- Department of Neurology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia
| | - Bruce V Taylor
- Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia
| | - Ernest Willoughby
- Department of Neurology, Auckland City Hospital, Grafton, New Zealand
| | - Fabienne Brilot
- Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.,Neuroimmunology Group, Kids Neurosciences Centre, Children's Hospital at Westmead, University of Sydney, Westmead, NSW, Australia
| | - Angela Vincent
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
| | - Patrick Waters
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
| | - Simon A Broadley
- Menzies Health Institute Queensland, Gold Coast, Griffith University, Southport, QLD, Australia.,Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia
| |
Collapse
|
46
|
Cepeda Martins AR, Di Maria S, Afonso J, Pereira M, Pereira J, Vaz P. Assessment of the uterine dose in digital mammography and digital breast tomosynthesis. Radiography (Lond) 2021; 28:333-339. [PMID: 34565679 DOI: 10.1016/j.radi.2021.09.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 09/03/2021] [Accepted: 09/06/2021] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Digital Mammography (DM-2D) and more recently Digital Breast Tomosynthesis (DBT), are two of the most effective imaging modalities for breast cancer detection, often used in screening programmes. It may happen that exams using these two imaging modalities are inadvertently performed to pregnant women. The objective of this study is to assess the dose in the uterus due to DM-2D and DBT exams, according to two main irradiation scenarios: in the 1st scenario the exposure parameters were pre-selected directly by the imaging system, while in the 2nd scenario, the maximum exposure parameters were chosen. METHODS The mammography equipment used was a Siemens Mammomat Inspiration. A physical anthropomorphic phantom, PMMA plates (simulating a breast thickness of 6 cm) and thermoluminescent dosimeters (TLDs) were used to measure entrance air kerma values on the phantom's breast and abdomen in order to successively estimate the mean glandular dose (MGD) and the dose in the uterus. For the two irradiation scenarios chosen, two-breast imaging modalities were selected: 1) DBT in Cranio-Caudal (CC) view (with 28 kV and 160 mAs as exposure parameters), 2) DBT and DM in Medio Lateral-Oblique (MLO) and CC views (with 34 kV and 250 mAs as exposure parameters). RESULTS In the 1st scenario, the TLD measurements did not detect significant dose values in the abdomen whereas the MGD estimated using the D.R. Dance model was in close agreement with data available in the literature. In the 2nd scenario, there was no significant difference in MGD estimation between the different views, whereas the air kerma values in the abdomen (in DBT mode, CC and MLO) were 0.049 mGy and 0.004 mGy respectively. In CC DM-2D mode the abdomen air kerma value was 0.026 mGy, with no significant detected value in MLO view. CONCLUSIONS For the dose in the uterus, the obtained values seem to indicate that DM-2D and DBT examinations inadvertently performed during pregnancy do not pose a significant radiological risk, even considering the case of overexposure in both breasts. IMPLICATIONS FOR PRACTICE The accurate knowledge of the doses in DM-2D and DBT will contribute to raise the awareness among medical practitioners involved in breast imaging empowering them to provide accurate information about dose levels in the uterus, improving their radiation risk communication skills and consequently helping to reduce the anxiety of pregnant women undergoing this type of examinations.
Collapse
Affiliation(s)
- A R Cepeda Martins
- Inspeção Geral da Agricultura, do Mar, do Ambiente, e do Ordenamento do Territorio (IGAMOT), Seção Radiações Ionizantes, Rua de O Seculo, N.51, 1200-433, Lisbon, Portugal
| | - S Di Maria
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Campus Tecnológico e Nuclear, Estrada Nacional 10, km 139,7, 2695-066, Bobadela LRS, Portugal.
| | - J Afonso
- Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
| | - M Pereira
- Agência Portuguesa do Ambiente, Departamento de Emergências e Proteção Radiológica, Divisão de Autorização e Segurança Nuclear, Rua da Murgueira 9 - Zambujal - Alfragide, 2610-124, Amadora, Portugal
| | - J Pereira
- Agência Portuguesa do Ambiente, Departamento de Emergências e Proteção Radiológica, Divisão de Autorização e Segurança Nuclear, Rua da Murgueira 9 - Zambujal - Alfragide, 2610-124, Amadora, Portugal
| | - P Vaz
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Campus Tecnológico e Nuclear, Estrada Nacional 10, km 139,7, 2695-066, Bobadela LRS, Portugal
| |
Collapse
|
47
|
Kashetsky N, Mukovozov IM, Pereira J, Manion R, Carter S, Alhusayen R. Patient experiences with hidradenitis suppurativa: the Hidradenitis Patient Experience survey. Clin Exp Dermatol 2021; 47:72-79. [PMID: 34235774 DOI: 10.1111/ced.14826] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 05/03/2021] [Accepted: 07/06/2021] [Indexed: 01/15/2023]
Abstract
BACKGROUND Better understanding of the experience of people living with hidradenitis suppurativa (HS) is essential to identify gaps in current patient care and inform healthcare decision-making. AIM To describe the patient experience of individuals with HS, including their path to diagnosis, symptom control, treatments, healthcare utilization, patient needs and impact on quality of life. METHODS The Hidradenitis Suppurativa Patient Experience survey was created, extensively reviewed and disseminated through engaging HS-related patient organizations, physician groups and social media groups. RESULTS In total, 537 respondents completed the survey; the mean age was 38 years (range 14-73 years) and 95% (510 of 537) were female. The mean number of treatment types per respondent was 15, and included antibacterial soaps (93.3%; 431 of 462), avoidance of tight clothing (90.9%; 419 of 462), use of oral antibiotics (79.7%; 368 of 462), nonprescription drugs (79.7%; 368 of 462) and topical antibiotics (77.1%; 356 of 262). Pain was poorly controlled in 46% of respondents (184 of 401). HS had a negative impact on the ability to work and attend school for 81% of respondents (337 of 415), with 59% (245 of 415) missing at least 2 days of work a month and 16% (66 of 415) missing > 11 days of work. The mean number of misdiagnoses per respondent was three and the median time to diagnosis was 10 years. CONCLUSION Individuals with HS experience a delay in diagnosis and have suboptimal control of the disease. We propose 11 recommendations to improve diagnosis, treatment and quality of life for individuals living with HS.
Collapse
Affiliation(s)
- N Kashetsky
- Faculty of Medicine, Memorial University of Newfoundland, St John's, NL, Canada
| | - I M Mukovozov
- Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
| | - J Pereira
- JRL Research & Consulting Inc, Mississauga, ON, Canada
| | - R Manion
- Canadian Skin Patient Alliance, Ottawa, ON, Canada
| | | | - R Alhusayen
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
48
|
Velasques RD, Silva WF, Bellesso M, Rocha V, Pereira J. PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: INTENSIFIED REGIMENS DO NOT IMPROVE OUTCOMES AS COMPARED TO RCHOP IN A RESOURCE‐CONSTRAINED SETTING. Hematol Oncol 2021. [DOI: 10.1002/hon.77_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- R. D. Velasques
- Instituto do Câncer do Estado de São Paulo Faculdade de Medicina da Universidade de São Paulo Division of Hematology São Paulo Brazil
| | - W. F. Silva
- Instituto do Câncer do Estado de São Paulo Faculdade de Medicina da Universidade de São Paulo Division of Hematology São Paulo Brazil
| | - M. Bellesso
- Instituto do Câncer do Estado de São Paulo Faculdade de Medicina da Universidade de São Paulo Division of Hematology São Paulo Brazil
| | - V. Rocha
- Instituto do Câncer do Estado de São Paulo Faculdade de Medicina da Universidade de São Paulo Division of Hematology São Paulo Brazil
| | - J. Pereira
- Instituto do Câncer do Estado de São Paulo Faculdade de Medicina da Universidade de São Paulo Division of Hematology São Paulo Brazil
| |
Collapse
|
49
|
Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, Skrypets T, De Souza CA, Hawkes EA, Fiad L, Lymboussakis A, Tomuleasa C, Nair R, Pereira J, Pereyra P, Minoia C, Kryachok I, de Castro NS, Advani RH, Luminari S. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0. Hematol Oncol 2021. [DOI: 10.1002/hon.135_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M Federico
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C. S Chiattone
- Santa Casa de Sao Paulo School of Medical Sciences São Paulo Brazil
| | - H. M Prince
- Epworth Healthcare, East Melbourne Richmond Australia
| | - A Pavlovsky
- Fundaleu, Haematology Buenos Aires Argentina
| | - M Manni
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - M Civallero
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - T Skrypets
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | | | - E. A Hawkes
- Lymphoma and Related Diseases Registry School of Public Health and Preventive Medicine Monash University and Olivia Newton John Cancer Research Institute Austin Health, Melbourne Australia
| | - L Fiad
- Hospital Italiano La Plata Department of Hematology and Oncology Buenos Aires Argentina
| | - A Lymboussakis
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C Tomuleasa
- Ion Chiricuta Oncology Institute Department of Hematology Cluj Napoca Romania
| | - R Nair
- TATA Medical Center, Clinical Haematology Oncology Kolkata India
| | - J Pereira
- Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina São Paulo Brazil
| | - P Pereyra
- Hospital Nacional Dr. Prof. Alejandro Posadas Hematology Buenos Aires Argentina
| | - C Minoia
- IRCCS Cancer Institute "Giovanni Paolo II" Haematology Unit Bari Italy
| | - I Kryachok
- National Cancer Institute Oncohematology Department Kiev Ukraine
| | - N. S de Castro
- Hospital de Cancer de Barretos, Hematology, Barretos São Paulo Brazil
| | - R. H Advani
- Stanford Cancer Center Blood and Marrow Transplant Program, Stanford California USA
| | - S Luminari
- Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, Hematology Unit and University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Reggio Emilia Italy
| |
Collapse
|
50
|
Bellesso M, Pereira J, Bassolli L, Abdo ANR, Junior WFS, Velasques RD, Brandão AAGS, Melo RB, Lage LAPC, Maciel FVR, Visnadi H, Shcolnik R, Duffles G, Beraldo JI, Duran A, Soares IC, Siqueira SAC, Rocha V. OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS TREATED IN A BRAZILIAN PUBLIC CANCER CENTER – A REAL WORLD EXPERIENCE OF 809 PATIENTS IN A 11 YEAR PERIOD. Hematol Oncol 2021. [DOI: 10.1002/hon.58_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M Bellesso
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - J Pereira
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - L Bassolli
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - A. N. R Abdo
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - W. F. S Junior
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - R. D Velasques
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | | | - R. B Melo
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - L. A. P. C Lage
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - F. V. R Maciel
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - H Visnadi
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - R Shcolnik
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - G Duffles
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - J. I Beraldo
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - A Duran
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| | - I. C Soares
- nstituto do Câncer do Estado de São Paulo, Pathology São Paulo Brazil
| | - S. A. C Siqueira
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Pathology São Paulo Brazil
| | - V Rocha
- Instituto do Câncer do Estado de São Paulo, Hematology São Paulo Brazil
| |
Collapse
|